Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W135 and Y conjugate vaccine (CanSino Biologics Inc.)
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Menhycia is a quadrivalent meningococcal conjugate vaccine (MCV4) developed by CanSino Biologics for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine consists of capsular polysaccharides from each of the four serogroups, each individually conjugated to the CRM197 carrier protein, which is a non-toxic mutant of the diphtheria toxin. This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, significantly enhancing immunogenicity and inducing immunological memory, particularly in infants and young children. Approved by China's National Medical Products Administration (NMPA) in December 2021, it was the first quadrivalent meningococcal conjugate vaccine to be marketed in China, providing broader protection than the previously available bivalent or polysaccharide-only vaccines.
- Brand names
- Menhycia
- Other names
- meningococcal ACYW135 polysaccharide conjugate vaccine (CRM197)MenACYW-CRM197MenACYW-CRM-197MenACYW-CRM 197
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A, C, W135 and Y conjugate vaccine (CanSino Biologics Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W135 and Y conjugate vaccine (CanSino Biologics Inc.).